Mirum Pharmaceuticals, Inc. MIRM Accounts payable, accrued expenses and other liabilities
Accounts payable, accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept mirm:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s accounts payable, accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s accounts payable, accrued expenses and other liabilities?
- Mirum Pharmaceuticals, Inc. (MIRM) reported accounts payable, accrued expenses and other liabilities of $57.24M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s accounts payable, accrued expenses and other liabilities changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s accounts payable, accrued expenses and other liabilities increased by 387.7% year-over-year, from $11.74M to $57.24M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s accounts payable, accrued expenses and other liabilities?
- Over 3 years (2022 to 2025), Mirum Pharmaceuticals, Inc.'s accounts payable, accrued expenses and other liabilities has grown at a 87.1% compound annual growth rate (CAGR), from $7.64M to $50.1M.
- What does accounts payable, accrued expenses and other liabilities mean?
- This metric tracks the net change in short-term obligations owed to suppliers, service providers, and other creditors. An increase indicates that the company is effectively utilizing trade credit to manage working capital, while a decrease suggests cash outflows to settle these liabilities. It serves as a primary indicator of short-term liquidity management.